National Cancer Institute; Notice of Meeting, 11363 [2017-03387]

Download as PDF Federal Register / Vol. 82, No. 34 / Wednesday, February 22, 2017 / Notices therapy, or as needing alternative treatment strategies. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Complete applications for a license in the prospective field of use that are filed in response to this notice will be treated as objections to the grant of the contemplated Exclusive Patent License Agreement. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: February 15, 2017. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2017–03402 Filed 2–21–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting sradovich on DSK3GMQ082PROD with NOTICES Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Board of Scientific Advisors. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will also be videocast and can be accessed from the NIH Videocasting and Podcasting Web site (https:// videocast.nih.gov/). Name of Committee: National Cancer Institute Board of Scientific Advisors. Date: March 21, 2017. Time: 8:30 a.m. to 5:00 p.m. Agenda: Acting Director’s Report: Ongoing and New Business; RFA and RFP Concept Reviews; and Scientific Presentations. Place: National Institutes of Health, 31 Center Drive, Building 31, C-Wing, 6th Floor, Room 10, Bethesda, MD 20892. VerDate Sep<11>2014 16:05 Feb 21, 2017 Jkt 241001 Contact Person: Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Rm. 7W444, Bethesda, MD 20892, 240–276–6340, grayp@ mail.nih.gov. Name of Committee: National Cancer Institute Board of Scientific Advisors. Date: March 22, 2017. Time: 8:30 a.m. to 12:00 p.m. Agenda: Acting Director’s Report: Ongoing and New Business; RFA and RFP Concept Reviews; and Scientific Presentations. Place: National Institutes of Health, 31 Center Drive, Building 31, C-Wing, 6th Floor, Room 10, Bethesda, MD 20892. Contact Person: Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Rm. 7W444, Bethesda, MD 20892, 240–276–6340, grayp@ mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: February 15, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03387 Filed 2–21–17; 8:45 am] BILLING CODE 4140–01–P PO 00000 11363 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Cancer Institute Clinical Trials and Translation Research Advisory Committee, March 8, 2017, 8:00 a.m. to March 8, 2017, 3:00 p.m., National Institutes of Health, Building 31, C-Wing, 6th Floor, Rooms 9 and 10, 31 Center Drive, Bethesda, MD 20892 which was published in the Federal Register on January 11, 2017, 81 FR 3342. This meeting notice is amended to change the meeting format and start and end times. The meeting will now be held virtually from 11:00 a.m. to 1:30 p.m. due to a change in the agenda which reduced the time required for deliberation and discussion. The meeting will still be held at the National Institutes of Health, Building 31, CWing, 6th Floor, Rooms 9 and 10, 31 Center Drive, Bethesda, MD 20892 and can also be accessed via NIH Videocast at https://videocast.nih.gov. This meeting is open to the public. Dated: February 16, 2017. Melanie J. Gray-Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–03448 Filed 2–21–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Aging; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Aging Special Emphasis Panel; Second Stage P01 Review. Date: March 15, 2017. Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\22FEN1.SGM 22FEN1

Agencies

[Federal Register Volume 82, Number 34 (Wednesday, February 22, 2017)]
[Notices]
[Page 11363]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03387]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of a meeting of the 
National Cancer Institute Board of Scientific Advisors.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting. The meeting will also be videocast and can be 
accessed from the NIH Videocasting and Podcasting Web site (https://videocast.nih.gov/).

    Name of Committee: National Cancer Institute Board of Scientific 
Advisors.
    Date: March 21, 2017.
    Time: 8:30 a.m. to 5:00 p.m.
    Agenda: Acting Director's Report: Ongoing and New Business; RFA 
and RFP Concept Reviews; and Scientific Presentations.
    Place: National Institutes of Health, 31 Center Drive, Building 
31, C-Wing, 6th Floor, Room 10, Bethesda, MD 20892.
    Contact Person: Paulette S. Gray, Ph.D., Director, Division of 
Extramural Activities, National Cancer Institute--Shady Grove, 
National Institutes of Health, 9609 Medical Center Drive, 7th Floor, 
Rm. 7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.

    Name of Committee: National Cancer Institute Board of Scientific 
Advisors.
    Date: March 22, 2017.
    Time: 8:30 a.m. to 12:00 p.m.
    Agenda: Acting Director's Report: Ongoing and New Business; RFA 
and RFP Concept Reviews; and Scientific Presentations.
    Place: National Institutes of Health, 31 Center Drive, Building 
31, C-Wing, 6th Floor, Room 10, Bethesda, MD 20892.
    Contact Person: Paulette S. Gray, Ph.D., Director, Division of 
Extramural Activities, National Cancer Institute--Shady Grove, 
National Institutes of Health, 9609 Medical Center Drive, 7th Floor, 
Rm. 7W444, Bethesda, MD 20892, 240-276-6340, grayp@mail.nih.gov.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: https://deainfo.nci.nih.gov/advisory/bsa/bsa.htm, where an 
agenda and any additional information for the meeting will be posted 
when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)


    Dated: February 15, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03387 Filed 2-21-17; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.